LANDONI, FABIO
 Distribuzione geografica
Continente #
NA - Nord America 18.917
AS - Asia 12.575
EU - Europa 8.247
SA - Sud America 2.060
AF - Africa 306
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 13
Totale 42.152
Nazione #
US - Stati Uniti d'America 17.941
SG - Singapore 4.986
CN - Cina 2.166
HK - Hong Kong 2.093
IT - Italia 1.831
RU - Federazione Russa 1.673
BR - Brasile 1.575
VN - Vietnam 1.516
SE - Svezia 973
IE - Irlanda 933
DE - Germania 890
CA - Canada 786
FR - Francia 408
UA - Ucraina 382
IN - India 376
GB - Regno Unito 351
BD - Bangladesh 246
FI - Finlandia 202
AR - Argentina 182
ID - Indonesia 158
KR - Corea 153
IQ - Iraq 140
TR - Turchia 133
MX - Messico 119
ZA - Sudafrica 114
NL - Olanda 101
AT - Austria 98
ES - Italia 97
JP - Giappone 87
PK - Pakistan 80
SA - Arabia Saudita 72
CO - Colombia 66
PH - Filippine 63
EC - Ecuador 60
VE - Venezuela 60
PL - Polonia 51
UZ - Uzbekistan 44
DK - Danimarca 41
CH - Svizzera 38
MA - Marocco 37
CL - Cile 34
PY - Paraguay 34
EG - Egitto 30
AU - Australia 27
TN - Tunisia 26
BE - Belgio 25
KE - Kenya 25
MY - Malesia 25
AE - Emirati Arabi Uniti 23
SK - Slovacchia (Repubblica Slovacca) 23
PE - Perù 22
RO - Romania 20
IL - Israele 18
JO - Giordania 18
AZ - Azerbaigian 17
IR - Iran 17
UY - Uruguay 17
PS - Palestinian Territory 16
CZ - Repubblica Ceca 15
JM - Giamaica 15
LT - Lituania 15
OM - Oman 15
DZ - Algeria 14
ET - Etiopia 14
CR - Costa Rica 13
KZ - Kazakistan 13
NG - Nigeria 13
TH - Thailandia 13
AL - Albania 12
NP - Nepal 12
LB - Libano 11
TW - Taiwan 11
BG - Bulgaria 10
BO - Bolivia 10
RS - Serbia 10
HN - Honduras 9
KG - Kirghizistan 9
PT - Portogallo 9
DO - Repubblica Dominicana 8
EU - Europa 8
PA - Panama 8
KW - Kuwait 7
MN - Mongolia 7
AO - Angola 6
HR - Croazia 6
SN - Senegal 6
BY - Bielorussia 5
GE - Georgia 5
HU - Ungheria 5
MD - Moldavia 5
NZ - Nuova Zelanda 5
BB - Barbados 4
BH - Bahrain 4
GR - Grecia 4
MU - Mauritius 4
NI - Nicaragua 4
NO - Norvegia 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
Totale 42.097
Città #
Singapore 2.941
Ann Arbor 2.072
Hong Kong 2.053
Ashburn 1.702
Fairfield 1.397
San Jose 1.081
Woodbridge 964
Dublin 894
Houston 776
Wilmington 691
Chandler 636
Toronto 633
New York 576
Santa Clara 549
Seattle 513
Cambridge 501
Frankfurt am Main 464
Milan 444
Princeton 442
Chicago 436
Ho Chi Minh City 394
Beijing 350
The Dalles 321
Hanoi 309
Jacksonville 297
Los Angeles 286
Dearborn 277
Hefei 267
Lauterbourg 236
Dallas 214
Lawrence 197
Altamura 167
São Paulo 148
Moscow 145
Seoul 144
Boardman 128
Helsinki 126
San Diego 119
Buffalo 113
Nanjing 106
Shanghai 103
Rome 98
Jakarta 96
London 92
Dong Ket 89
Guangzhou 85
Andover 82
Hamburg 75
Munich 74
Council Bluffs 66
Tokyo 64
Nuremberg 61
Vienna 60
Fremont 59
Haiphong 58
Baghdad 56
Rio de Janeiro 56
Atlanta 55
Chennai 51
Da Nang 50
Orem 50
Salt Lake City 50
Mumbai 46
Johannesburg 44
Lachine 41
Montreal 41
Brooklyn 40
Curitiba 40
Tashkent 40
Dhaka 38
Tianjin 38
Phoenix 35
Warsaw 34
Biên Hòa 33
Norwalk 33
Bologna 30
Brasília 30
Denver 30
Lissone 30
Falls Church 29
Nanchang 29
Pune 28
Shenyang 28
Boston 26
Naples 26
Riyadh 26
San Francisco 26
Stockholm 26
Amsterdam 25
Turin 25
Changsha 24
Elk Grove Village 24
Manchester 24
Porto Alegre 24
Jinan 23
Mexico City 23
Nairobi 23
Shenzhen 23
Hebei 22
Lahore 22
Totale 26.788
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 574
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 534
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3 461
Combining positron emission tomography/computed tomography, radiomics, and sentinel lymph node mapping for nodal staging of endometrial cancer patients 442
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 427
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 403
Prevalence of human papillomavirus (HPV) and other sexually transmitted infections (STIS) among italian women referred for a colposcopy 390
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 380
Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis 364
Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: a retrospective cohort comparison 359
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 354
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 351
Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers 339
European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer 306
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer 302
The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study 296
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 288
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 286
Prevalence of Chlamydia trachomatis Infection, Serovar Distribution and Co-Infections with Seven High-Risk HPV Types among Italian Women with a Recent History of Abnormal Cervical Cytology 282
Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy 279
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: A prospective randomized study 276
The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy 267
The clinical significance of the tumor marker CA-125 261
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 260
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 258
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 258
Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial 256
Uterine leiomyosarcoma: analysis of treatment failures and survival 250
Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk 248
Onclarity Human Papillomavirus Extended Genotyping in the Management of Cervical Intraepithelial Neoplasia 2+ Lesions 246
Accuracy of Human Papillomavirus (HPV) Testing on Urine and Vaginal Self-Samples Compared to Clinician-Collected Cervical Sample in Women Referred to Colposcopy 240
Association between physical activity and menstrual cycle disorders in young athletes 238
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 237
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 235
Borderline ovarian cancer 234
Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Pathogens in Cervical and Self-Collected Specimens 231
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 231
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma 231
Evaluation of two alternative non-alcohol-based media for the suspension of self-collected vaginal swabs for HPV testing in cervical cancer screening 227
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 221
Endometrial stromal sarcoma: analysis of treatment failures and survival 220
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 219
Oncologic and obstetric outcomes after simple conization for fertility-sparing surgery in FIGO 2018 stage IB1 cervical cancer 219
Fertility outcomes in stage I ovarian immature teratomas 218
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 218
Evaluation of BD Onclarity™ HPV Assay on Self-Collected Vaginal and First-Void Urine Samples as Compared to Clinician-Collected Cervical Samples: A Pilot Study 215
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 215
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 215
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 214
Neoadjuvant platinum-based chemotherapy followed by radical hysterectomy for stage Ib2-IIb adenocarcinoma of the uterine cervix – An Italian multicenter retrospective study 211
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 210
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer 210
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 210
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 210
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells 209
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 208
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer 208
Cancer in pregnancy: Proposal of an italian multicenter study. gynecologic oncology group of the italian society of gynecology and obstetrics (sigo) 207
Anatomical Spaces in Radical Hysterectomy for Cervical Cancer 206
Chemo-conization in early cervical cancer 206
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 206
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 206
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 206
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 203
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 202
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture 201
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 200
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 200
Reduction of postoperative complication rate with the use of early oral feeding in gynecologic oncologic patients undergoing a Major surgery: A randomized controlled trial 200
The clinical implementation of primary HPV screening 197
Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic 196
Endometriosis-related spontaneous hemoperitoneum in pregnancy: A case series 194
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study 194
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 192
European society of gynaecological oncology guidelines for the management of patients with Vulvar cancer 192
Radical Hysterectomy in Early-Stage Cervical Cancer: Abandoning the One-Fits-All Concept 190
Fertility-Sparing Options in Young Women with Cervical Cancer 190
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study 189
Randomized study between radical surgery and radiotherapy for the treatment of stage IB–IIA cervical cancer: 20-year update 188
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series 187
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer 186
DNA index of ovarian carcinomas from 56 patients: In vivo in vitro studies 185
Eviscerazione pelvica 185
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 184
Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis 182
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 182
Colposcopy Accuracy and Diagnostic Performance: A Quality Control and Quality Assurance Survey in Italian Tertiary-Level Teaching and Academic Institutions—The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV) 181
Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience 181
Chlamydia trachomatis infection and HPV/Chlamydia trachomatis co-infection among HPV-vaccinated young women at the beginning of their sexual activity 181
Teniposide in refractory ovarian cancer: a phase II study 180
Low-Volume Metastases in Apparent Early-Stage Endometrial Cancer: Prevalence, Clinical Significance, and Future Perspectives 178
Low-Volume Metastases in Cervical Cancer: Does Size Matter? 177
Repair of the Perineal Defect After Radical Vulvar Surgery: Direct Closure Versus Skin Flaps Reconstruction: A Retrospective Comparative Study 177
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer 175
Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit 173
Evaluation of the interaction of mononuclear phagocytes with ovarian carcinoma cells in a colony assay 172
Pelvic exenteration: Ten-year experience at the European Institute of Oncology in Milan 171
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 170
Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancer 169
Mitozolomide activity on human cancer cells in vitro 169
Totale 24.061
Categoria #
all - tutte 155.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.573


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021691 0 0 0 0 0 0 0 0 0 0 285 406
2021/20222.661 162 322 368 170 160 164 127 169 129 199 212 479
2022/20233.348 477 912 250 221 228 561 58 172 254 32 90 93
2023/20242.974 73 63 180 123 432 688 553 67 310 68 52 365
2024/20258.222 408 1.160 600 381 662 332 405 242 920 1.216 612 1.284
2025/202616.445 1.627 1.174 1.338 1.934 1.967 971 2.605 1.081 1.474 1.326 948 0
Totale 43.240